Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Tharos who wrote (4199)	10/21/1997 12:36:00 AM
From: chirodoc	Read Replies (1) \| Respond to of 17367

<<<<<<I think it would be fairer to say that companies with earnings don't get hit as hard ..........true enough

To: Tharos who wrote (4199)	10/21/1997 6:41:00 PM
From: Andrew H	Read Replies (1) \| Respond to of 17367

>>.....i agree, but i think that andrew h was saying that co's without earnings can be hit hard in a crash<< Chirodoc, I think it would be fairer to say that companies with earnings don't get hit as hard.<< Well, not sure what the real difference is between the two. Of course everyone gets hard hit in a crash. Those without earnings most likely get hit harder than those with earnings. Those with earnings most likely get hit less hard than those without. In my post, I was just trying to emphasize the inherent riskiness of companies like XOMA, where if BPI fails (perish the thought!) or even has difficulty showing efficacy in such a difficult indication as hem trauma, the future will be very questionable.